Join the Byetta group to help and get support from people like you.
Byetta News
GLP-1 Drugs Appear To Lower Cancer Risk
MONDAY, May 19, 2025 — Cutting-edge GLP-1 weight-loss drugs appear to help lower cancer risk even beyond the benefits from dropping excess pounds, a new study says. First-generation GLP-1 drugs like l...
Study Finds Exenatide Not Beneficial for Parkinson Disease
FRIDAY, Feb. 7, 2025 – The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, according to a study published online Feb. 4 in...
Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds
WEDNESDAY, Feb. 5, 2025 – Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit. A new study found that a drug in the same class called exenatide,...
More Evidence That GLP-1 Meds Curb Alcohol Abuse
FRIDAY, Nov. 15, 2024 – There have been a slew of studies recently supporting the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to curb problem...
GLP-1 RA Use Linked to Retained Gastric Contents During Endoscopies
FRIDAY, Oct. 4, 2024 – Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with the risk for retained gastric contents and inadequate bowel preparation during endoscopic...
FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions
ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...
FDA Medwatch Alert: Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication - Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas
ISSUE: FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis and pre-cancerous cellular changes called pancreatic duct...
Byetta Approved for Use with Insulin Glargine in the U.S.
SAN DIEGO and INDIANAPOLIS, Oct. 19, 2011 /PRNewswire/ – Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has approved a new...
Byetta Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
SAN DIEGO and INDIANAPOLIS, Oct. 30, 2009 /PRNewswire-FirstCall/ – Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Medwatch Alert: Byetta (exenatide)
[UPDATED 08/18/2008] Since issuing Information for Healthcare Professionals in October 2007, FDA has received reports of 6 cases of hemorrhagic or necrotizing pancreatitis in patients taking Byetta....